Hbvaxpro (Aluminium, Hepatitis B Surface Antigen (Rdna) [produced In S. Cerevisiae Cells By Rdna])

Hbvaxpro is indicated for the active immunization against hepatitis B virus infection in persons who have not been previously vaccinated or who require a booster dose.

• Primary prevention of hepatitis B infection in infants, children, and adults.
• Post‑exposure prophylaxis for individuals with recent exposure to hepatitis B virus.
• Booster vaccination for persons with waning anti‑HBs antibody levels.
• Immunization of healthcare workers and others at occupational risk.
• Use in travel medicine for persons traveling to regions with high hepatitis B prevalence.

The safety profile of Hbvaxpro reflects that of other recombinant hepatitis B vaccines; most reactions are mild and transient.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Fatigue or mild headache.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face.
• Neurological events such as Guillain‑Barré syndrome, though rare.
• Persistent high fever or seizures.

Before administering Hbvaxpro, healthcare providers should evaluate patient history and current health status to minimize risk of adverse events.

• Do not vaccinate individuals with a known severe allergy to any vaccine component, including aluminium salts.
• Defer vaccination in persons experiencing moderate or severe acute illness until recovery.
• Use caution in patients with a history of hypersensitivity to yeast proteins.
• Monitor for signs of anaphylaxis for at least 15 minutes after injection.
• Discuss the benefits and risks of vaccination with pregnant or lactating women, as safety data are limited.
• Consider serologic testing to assess immunity in individuals with uncertain vaccination status.

Hbvaxpro does not have many documented drug‑drug interactions, but certain concomitant therapies may influence immune response or increase adverse‑event risk.

Avoid

• Simultaneous administration of other live vaccines (e.g., measles, mumps, rubella) in the same injection site.
• Use of systemic corticosteroids or immunosuppressive agents at high doses during the vaccination series.

Use with caution

• Moderate immunosuppression (e.g., low‑dose steroids, chemotherapy) may reduce antibody response.
• Antipyretics such as acetaminophen or ibuprofen can be taken to manage mild post‑vaccination fever.
• Patients receiving blood products or immunoglobulins should have vaccination timing coordinated to avoid interference with antibody development.